| 06/08/2026 3:04 PM | aTyr Pharma (1339970) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/05/2026 9:13 AM | aTyr Pharma (1339970) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G/A | |
| 06/01/2026 3:04 PM | aTyr Pharma (1339970) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/15/2026 7:02 AM | aTyr Pharma (1339970) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/13/2026 3:17 PM | aTyr Pharma (1339970) Issuer Coughlin Timothy (1376043) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/11/2026 3:03 PM | aTyr Pharma (1339970) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/26/2026 3:08 PM | aTyr Pharma (1339970) Subject VANGUARD GROUP INC (102909) Filed by | Form SCHEDULE 13G/A | |
| 03/26/2026 3:09 PM | aTyr Pharma (1339970) Filer | Form DEFA14A | |
| 03/26/2026 3:10 PM | aTyr Pharma (1339970) Filer | Form ARS | |
| 03/05/2026 3:11 PM | aTyr Pharma (1339970) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/04/2026 6:12 PM | aTyr Pharma (1339970) Issuer DENYES NANCY (1640869) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for ATYR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.
|
| 02/04/2026 6:15 PM | aTyr Pharma (1339970) Issuer Broadfoot Jill Marie (1305178) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/04/2026 6:17 PM | aTyr Pharma (1339970) Issuer Shukla Sanjay (1671026) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/09/2026 4:42 PM | aTyr Pharma (1339970) Issuer Broadfoot Jill Marie (1305178) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/09/2026 4:46 PM | aTyr Pharma (1339970) Issuer Shukla Sanjay (1671026) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/09/2026 4:40 PM | aTyr Pharma (1339970) Issuer DENYES NANCY (1640869) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/05/2025 3:05 PM | aTyr Pharma (1339970) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/06/2025 3:17 PM | aTyr Pharma (1339970) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/09/2025 5:30 PM | aTyr Pharma (1339970) Issuer SCHIMMEL PAUL (1236447) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/07/2025 10:03 AM | aTyr Pharma (1339970) Subject FEDERATED HERMES, INC. (1056288) Filed by FEDERATED HERMES, INC. (1056288) Filed by | Form SCHEDULE 13G/A | |
| 09/15/2025 7:30 AM | aTyr Pharma (1339970) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/18/2025 11:15 PM | aTyr Pharma (1339970) Filer | Form EFFECT | |
| 08/07/2025 8:33 PM | aTyr Pharma (1339970) Filer | Form 8-K/A | |
| 07/29/2025 10:24 AM | aTyr Pharma (1339970) Subject VANGUARD GROUP INC (102909) Filed by | Form SCHEDULE 13G | |
| 07/17/2025 7:12 PM | aTyr Pharma (1339970) Subject BlackRock, Inc. (2012383) Filed by | Form SCHEDULE 13G | |